Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aglatimagene Besadenovec + Pembrolizumab vs Docetaxel in Stage IV Non-Squamous NSCLC
NCT07660094Phase 3Recruiting
- Sponsor
- Candel Therapeutics
- Start
- Jun 2026
- Primary completion
- Oct 2031
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aglatimagene besadenovec in Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC) (2 arms), sponsored by Candel Therapeutics. Primary endpoint: Overall Survival at 24 months. Started Jun 2026; status: recruiting.
02
Drugs
aglatimagene besadenovec
03
Conditions
Nonsquamous Non-Small Cell Lung Cancer (nsNSCLC)
Beyond the preview
Go deeper on NCT07660094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07660094.